Antimicrobial Resistance in Campylobacter coli and Campylobacter jejuni from Human Campylobacteriosis in Taiwan, 2016 to 2019-Reference-Cited by-同舟云学术

Antimicrobial Resistance in Campylobacter coli and Campylobacter jejuni from Human Campylobacteriosis in Taiwan, 2016 to 2019

Published:2022-01-18 Issue:1 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Liao Ying-Shu¹,Chen Bo-Han¹,Teng Ru-Hsiou¹,Wang You-Wun¹,Chang Jui-Hsien¹,Liang Shiu-Yun¹,Tsao Chi-Sen¹,Hong Yu-Ping¹²,Sung Hui-Yung¹,Chiou Chien-Shun¹^ORCID

Affiliation:

1. Center for Diagnostics and Vaccine Development, Centers for Disease Control, Taichung, Taiwan

2. National Chung Hsing University, Taichung, Taiwan

Abstract

Campylobacter coli and Campylobacter Jejuni are highly resistant to most therapeutic antimicrobials in Taiwan; rapid diagnostics of resistance in bacterial isolates is crucial for the treatment of campylobacteriosis. We characterized 219 (40 C. coli and 179 C. jejuni ) isolates recovered from humans from 2016 to 2019 using whole-genome sequencing to investigate the genetic diversity among isolates and the genetic resistance determinants associated with antimicrobial resistance.

Funder

Ministry of Health and Welfare

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01736-21

Reference63 articles.

1. The clinical importance of emerging Campylobacter species

2. Global Epidemiology of Campylobacter Infection

3. Source attributed case-control study of campylobacteriosis in New Zealand